Webinar Technology

Cell analysis: Time for a change?

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Cell analysis: Time for a change?

Recorded 28 June 2017


The traditional techniques of standard microscopy and flow cytometry have been the stalwart of cell analysis for many years. But times have changed—scientific breakthroughs, grant applications, and publications wait for no one—and there are now a host of new technologies that complement these traditional modalities. With the advent of automation and high-throughput technologies, researchers no longer need to spend hours in a darkroom to capture a simple fluorescent image, painstakingly measuring cell parameters one cell at a time, or risk losing precious samples due to mechanical issues. Our panelists will explain how applying the latest cutting-edge technologies, such as high-content analysis and superresolution microscopy, as well as other advances in flow cytometry and microscopy, can lead to new discoveries while saving time and making your lab more efficient and productive.

During the webinar, the speakers will:

  • Discuss how recent advances have led to breakthroughs, including the ability to measure rare events in cancer stem cells or 3D structures such as organoids
  • Elucidate how new technologies can positively impact the day-to-day operation of your lab
  • Explain how reagents can influence results and why reagent validation is critical.

This webinar will last for approximately 60 minutes

Speaker bios

Andrea Cossarizza, M.D., Ph.D.

University of Modena and Reggio Emilia School of Medicine
Modena, Italy

Dr. Cossarizza completed his M.D. degree at the University of Padova in Italy before receiving a Ph.D. in oncology from the University of Modena and Reggio Emilia (UNIMORE) and the University of Bologna, also in Italy. After specializing in clinical pathology at UNIMORE, he obtained an associate professorship there. In 2005, he was appointed a professor in the international Ph.D. program at the University of Valencia in Spain, where he later became a research professor. In 2010, he became a full professor in pathology and immunology in the Faculty of Medicine at UNIMORE. He is a member of several editorial boards of international journals, and in 2016 was elected president of the International Society for Advancement of Cytometry. His primary research focus is identifying the molecular and cellular basis for the involvement of the immune system in diseases and infections, including HIV/AIDS and sepsis, as well as its role in pathophysiological conditions related to aging and neurodegeneration. Dr. Cossarizza has notable experience in the development and use of new flow cytometry approaches in immunological research.

Jens Peter Von Kries, Ph.D.

Research Institute for Molecular Pharmacology (FMP)
Berlin, Germany

Dr. Von Kries is senior scientist and head of the Screening Unit at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), the Max-Delbrück Center for Molecular Medicine (MDC), and the Berlin Institute of Health (BIH). Prior to joining FMP, he was head of the Screening Unit at Semaia Pharmaceuticals in Berlin/Dortmund, Germany. He received his doctorate at the University Hospital Hamburg-Eppendorf in Hamburg, Germany, where he also held a postdoctoral position studying chromatin organization. He completed additional postdoctoral work at MDC, studying Wnt-signaling and protein interactions, before joining Semaia Pharmaceuticals. His current research focuses on assay development and optimization for drug screening, specifically the development of automated object identification routines for high-content screening using cellular model systems, for application in cancer development and metastasis research.

Christoph Hergersberg, Ph.D.

Thermo Fisher Scientific
Eugene, OR

Dr. Hergersberg is vice president of R&D for Thermo Fisher Scientific’s Protein and Cell Analysis and Antibody and Immunoassay businesses, based in Eugene, Oregon. In this role, he is responsible for R&D project delivery as well as organizational and strategic planning. He came to Thermo Fisher Scientific in 2014 from BD Biosciences, where he was a vice president for R&D. Prior to this, he worked at the General Electric Global Research Center (GRC) as global technology leader for biosciences, where he built the Global Technology Organization for Biosciences. He joined the GRC in 2004 after working at Amersham Biosciences, where he was a vice president for R&D. Before coming to Amersham, he was chief scientific officer at Xantos Biomedicine in Munich, Germany, where he built and directed a highly qualified team of more than 40 scientists working in the field of high-throughput functional biology. Prior to joining Xantos, he held positions at Boehringer Mannheim/Roche Diagnostics in the United States (director of technology management in the Chief Technology Office) and Boehringer Mannheim’s biopharmaceutical R&D division in Penzberg, Germany (project leader in biotechnology). A biologist by training, he received his doctorate in molecular cell biology and protein chemistry from the University of Munich and his postdoctoral training in immunology.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here